Tecentriq (atezolizumab), identified risk of severe cutaneous adverse reactions (SCARs) direct healthcare professional communication (DHPC)

 
Download this file (ENG Tecentriq DHPC - Severe Cutaneous Adverse Reactions with Atezolizumab.0.1.pd)Download[09.02.2021]